Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/191786
Title: A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets
Author: Herzog, Chiara
Marín, Fátima
Jones, Allison
Evans, Iona
Reisel, Daniel
Redl, Elisa
Schreiberhuber, Lena
Paytubi Casabona, Sònia
Pelegrina, Beatriz
Carmona, Álvaro
Peremiquel Trillas, Paula
Frias Gomez, Jon
Pineda, Marta
Brunet, Joan
Ponce, Jordi
Matias-Guiu, Xavier
Sanjosé, Silvia de
Alemany, Laia
Olaitan, Adeola
Wong, Michael
Jurkovic, Davor
Crosbie, Emma J.
Rosenthal, Adam N.
Bjørge, Line
Zikan, Michal
Dostalek, Lukas
Cibula, David
Sundström, Karin
Dillner, Joakim
Costas, Laura
Widschwendter, Martin
Keywords: Càncer d'endometri
Epigenètica
Endometrial cancer
Epigenetics
Issue Date: 20-Nov-2022
Publisher: American Society of Clinical Oncology (ASCO)
Abstract: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival.METHODSWe developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86).RESULTSWe describe the Women's cancer risk IDentification - quantitative polymerase chain reaction test for Endometrial Cancer (WID-qEC), a three-marker test that evaluates DNA methylation in gene regions of GYPC and ZSCAN12. In cervical, self-collected, and vaginal swab samples derived from symptomatic patients, it detected EC with sensitivities of 97.2% (95% CI, 90.2 to 99.7), 90.1% (83.6 to 94.6), and 100% (63.1 to 100), respectively, and specificities of 75.8% (63.6 to 85.5), 86.7% (79.3 to 92.2), and 89.1% (77.8 to 95.9), respectively. The WID-qEC identified 90.9% (95% CI, 70.8 to 98.9) of EC cases in samples predating diagnosis up to 1 year. Test performance was similar across menopausal status, age, stage, grade, ethnicity, and histology.CONCLUSIONThe WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits.
Note: Reproducció del document publicat a: https://doi.org/10.1200/JCO.22.00266
It is part of: Journal of Clinical Oncology, 2022, vol. 40, issue. 33, p. 3828-3838
URI: http://hdl.handle.net/2445/191786
Related resource: https://doi.org/10.1200/JCO.22.00266
ISSN: 1527-7755
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
jco.22.00266.pdf877.58 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons